Observational studyPharmacological reports : PR2026
Achieving target plasma concentrations of beta-lactam antibiotics in critically ill patients: a retrospective study of full-dose administration in the first 24 hours.
Observational study in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBeta-lactams are the cornerstone of therapy for the treatment of the most serious infections in the intensive care unit (ICU) setting. However, individualization of dosing remains challenging because pharmacokinetics are highly variable and difficult to predict in critically ill patients. The objective of this study was to evaluate whether administration of full-dose beta-lactam antibiotics to critically ill subjects during the first 24 h of treatment, irrespective of baseline renal function, achieves predefined target concentration ranges (Cmin [free minimum concentration] 1–10 × MIC [minimum inhibitory concentration] and 4–10 × MIC).
methodsThis trial was a retrospective, observational cohort study. A total of 377 critically ill patients over 18 years admitted to the ICU who received full doses of meropenem, piperacillin–tazobactam, or cefepime were analyzed. Blood sampling for determination of antibiotic trough concentration was performed 24 h after initiation of full-dose therapy.
resultsWhen targeting a Cmin of 4–10 × MIC, a high proportion of patients remained underdosed (42.7%, N = 161). In contrast, when targeting a Cmin of 1–10 × MIC, only 13.3% (N = 50) of patients failed to reach the target range. Seventy-four patients (19.6%) were found to be above the defined target range (Cmin > 10 × MIC). Reduced glomerular filtration rate (GFR) was a consistent independent predictor of achieved plasma level across the overall population, as well as within individual subsets. No adverse effects (neurotoxicity, hematotoxicity, hepatotoxicity) were observed.
conclusionsWith full-dose beta-lactam administration, targeting a Cmin of 4–10 × MIC results in a high proportion of patients being underdosed, whereas a target of 1–10 × MIC is achieved in the majority of patients. Our results highlight the importance of therapeutic drug monitoring (TDM) of beta-lactam antibiotics in critically ill patients. Further research in this field is warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.